RealTime Dynamix™: Inflammatory Bowel Disease US Q1 2018 Spotlight
What patient types do US gastroenterologists (n=101) associate with different biologics for UC & Crohn’s? To what extent will these patient type associations protect the brands in the face of newer entrants, such as Xeljanz? See complimentary highlights from the Q1 2018 wave of RealTime Dynamix™: Inflammatory Bowel Disease US to find out the answers to these questions and more.
Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.